Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | TRPC1 | P48995 | 2/20 | 0.53 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.53 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.53 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.53 |
| ▸ | STIM2 | Q9P246 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31252546 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1HPGDMAPTTRPC1 | |
| SCHEMBL1402810 | 0.87 | TRPC1 (0.62) | KDM4EALDH1A1HPGDMAPTTRPC1 | |
| SCHEMBL30147733 | 0.86 | TRPC1 (0.52) | KDM4EALDH1A1HPGDMAPTTRPC1 | |
| SCHEMBL21604844 | 0.86 | TRPC1 (0.52) | KDM4EALDH1A1HPGDMAPTTRPC1 | |
| SCHEMBL18706884 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1HPGDMAPTTRPC1 | |
| SCHEMBL31117196 | 0.84 | HTT (0.72) | KDM4EALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL4161763 | 0.84 | HTT (0.72) | KDM4EALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL26125572 | 0.83 | MAPT (0.67) | KDM4EALDH1A1MAPTKMT2ATDP1 | |
| SCHEMBL31252567 | 0.83 | MAPT (0.67) | KDM4EALDH1A1MAPTKMT2ATDP1 | |
| SCHEMBL21604941 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1HPGDMAPTTRPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | RAREFIED BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4499611-A1 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119032083-A | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2023192506-A1 | MALT1 MODULATORS AND USES THEREOF | RARIFIED BIOSCIENCES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | SMITHKLINE BEECHAM, PLC | 2005-10-27 | — | — | US | disclosed |
| EP-1228043-B1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1228043-A1 | ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032626-A1 | ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | MALT1, SQSTM1, PPP1R10 | KDM4E 2044/4885ALDH1A1 3447/4885HPGD 3460/4885 |
| US-20050239797-A1 | Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity | HTR1B, HTR1A, HTR1D | KDM4E 3839/4885ALDH1A1 489/4885HPGD 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.